Sernova (TSX:SVA; OTCQB:SEOVF; FSE/XETRA:PSH) appointed Cynthia Pussinen as CEO and a member of the board, succeeding Dr. Philip Toleikis, who will serve as chief technology officer. Ms. Pussinen’s expertise spans...
Frank Shannon Sernova (TSXV:SVA; OTC:SEOVF; FSE/XETRA:PSH) appointed 25-year pharmaceutical industry executive, Frank Shannon, as VP of clinical development and regulatory Affairs. Mr. Shannon most recently served...
Sernova (TSXV:SVA; OTC:SEOVF; FSE:PSH) reported additional positive preliminary safety and efficacy data for its Cell Pouch transplanted with insulin producing cells in patients with Type 1 diabetes. Data presented at...
Sernova’s (TSXV:SVA; OTCQB:SEOVF) Cell Pouch System, composed of an implantable device, therapeutic cells and immune protection technologies, has the potential to be a “functional cure” for millions of people with Type...
Leede Jones Gable launched coverage of Sernova (TSXV:SVA) with a “speculative buy” rating and price target of $1.00 (Canadian). The stock was quoted at 44 cents in early trading on Dec. 15. “We are positive on the...